Last updated: February 15, 2026
NDC 65038-0056 is a drug manufactured by Amneal Pharmaceuticals, identified as Amphetamine and Dextroamphetamine Sulfate Oral Suspension, 10 mg/5 mL. It serves primarily to treat Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. This report provides a comprehensive overview of its market landscape, competitive position, regulatory environment, and price trajectory.
Current Market Landscape
Product Details:
| Attribute |
Details |
| NDC Number |
65038-0056 |
| Drug Name |
Amphetamine and Dextroamphetamine Sulfate Oral Suspension |
| Strength |
10 mg/5 mL |
| Manufacturer |
Amneal Pharmaceuticals |
| Approval Date |
January 27, 2023 |
Indications:
- ADHD in children and adults
- Narcolepsy treatment
Distribution Channels:
- Pharmacy networks
- Specialty clinics
- Institutional healthcare providers
Market Size (U.S.):
- Estimated retail pharmacy sales in 2022: ~$350 million
- Growth rate (CAGR 2021–2026): 4.8% (Source: IQVIA)
Competition:
Main competitors include:
- Adderall XR (Shire/Takeda): The market leader, with approximately 50% market share.
- Generic Amphetamines: Multiple providers with a combined market share of 30%.
- Other formulations (e.g., instant-release): Remaining share.
Market Trends:
- Growing prevalence of ADHD diagnoses (approx. 10 million diagnosed in the U.S. in 2022).
- Increased demand drives generic substitution.
- Prescriber preferences shifting toward formulations with improved stability and tolerability.
Regulatory Environment
- FDA approved on January 27, 2023.
- Classified as a controlled substance (Schedule II).
- Patent landscape: No recent patent disputes, but existing patents on brand products (e.g., Adderall XR) impact generic entry timing.
Market Dynamics
Pricing Factors:
- Brand name: Approximate retail price (ARP) per 30 mL bottle (Adderall XR) ranges from $280–$350.
- Generic equivalents: Typically 30–40% cheaper; ARP ranges from $170–$210.
- Amneal's product: Launch price is projected at a slight discount (~15–20%) to existing generics to gain market share.
Reimbursement Landscape:
- Medicare Part D covers ADHD medications.
- Formularies favor generics due to cost-efficiency.
- Price erosion is expected as more generics enter and prescribers prefer cost-effective options.
Price Projections (2023–2028)
| Year |
Estimated Average Wholesale Price (AWP) |
Expected Retail Price |
Market Trends |
| 2023 |
~$180 per 30 mL |
~$210 per 30 mL |
Launch period, market entry stabilization |
| 2024 |
~$175 per 30 mL |
~$200 per 30 mL |
Increased generic competition, price stabilization begins |
| 2025 |
~$165 per 30 mL |
~$190 per 30 mL |
Continued market saturation, slight price decline |
| 2026 |
~$160 per 30 mL |
~$180 per 30 mL |
Market deepens with multiple generics |
| 2027 |
~$155 per 30 mL |
~$170 per 30 mL |
Market maturation, pricing stabilizes at lower levels |
| 2028 |
~$150 per 30 mL |
~$160 per 30 mL |
Peak generic penetration, cost-based pricing |
Variables influencing prices:
- Patent and exclusivity status: No exclusivity beyond initial approval.
- Manufacturing costs: Slight decline as production scales.
- Market penetration: Higher generic competition leading to aggressive price reductions.
- Regulatory changes: Stricter controls on controlled substances could impact distribution.
Implications for Stakeholders
- Pharmaceutical companies: Entry of generics is likely to suppress prices, encouraging cost-effective treatment options.
- Payers: Will push for formulary preference toward lowest-priced generics.
- Prescribers: Sensitive to cost; price fluctuations may influence prescribing patterns.
- Patients: Experience benefits from lower co-pays due to competitive pricing.
Key Takeaways
- NDC 65038-0056 recently launched into an already competitive market dominated by established brands and multiple generic producers.
- The product is positioned as a cost-effective alternative, with initial pricing expectations slightly below existing generics.
- Market prices are poised to decrease further over the next five years driven by increased generic competition.
- Regulatory and patent landscapes remain stable, with no immediate patent hurdles expected.
- Continued growth in ADHD diagnosis and prescription rates supports sustained product demand.
FAQs
1. How does the launch of NDC 65038-0056 impact existing market leaders?
It introduces additional generic options, increasing competition and placing downward pressure on prices.
2. What factors could alter the projected price trends?
Regulatory changes, patent disputes, supply chain disruptions, or shifts in prescribing patterns could influence prices.
3. What is the significance of Schedule II classification?
It restricts prescribing, dispensing, and handling, impacting distribution channels and pricing strategies.
4. Are there any differentiation factors for Amneal's product?
As a generic, differentiation is limited; price, availability, and prescriber familiarity are primary competitive factors.
5. How do reimbursement policies affect market pricing?
Reimbursement standards incentivize payers to favor lower-cost generics, accelerating price declines.
References
- IQVIA. "2022 National Prescription Audit."
- U.S. Food and Drug Administration. "ANDA Approval Records."
- Wolters Kluwer. "Pharmaceutical Price Trends & Market Dynamics."
- FDA. "Controlled Substances Act."
- Medicare.gov. "Formulary & Prescription Drug Coverage."
